A Phase I, Prospective, Randomized, Double-blind, Placebo-controlled, Sequential-cohort, Escalating, Single-dose Study Designed to Determine the Maximum Tolerated Oral Dose of NW-3509A in Healthy, Male Volunteers

Trial Profile

A Phase I, Prospective, Randomized, Double-blind, Placebo-controlled, Sequential-cohort, Escalating, Single-dose Study Designed to Determine the Maximum Tolerated Oral Dose of NW-3509A in Healthy, Male Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Evenamide (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors Newron Pharmaceuticals; Newron Sweden AB
  • Most Recent Events

    • 03 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 08 Apr 2014 Preliminary results have been presented at the 4th Biennial Schizophrenia International Research Society (SIRS) Conference according to a Newron Pharmaceuticals media release.
    • 17 Jan 2014 As per the ClinicalTrials.gov record, planned number of patients changed from 27 to 45.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top